O7.13 Testosterone deficiencies and supplementation.O7.11 Combined Pulmonary Fibrosis and Emphysema.O7.8 Gastro-oesophageal reflux disease (GORD).O7.2.5 Coronary revascularisation procedures.O7.1 Increased risks from comorbidities in the presence of COPD.O6.8 Chest physiotherapy (Airway clearance techniques).O6.5 Physical activity and sedentary behaviour.O6.4 Neuromuscular Electrical Stimulation.O4.2.1 Eosinophil count and inhaled corticosteroids.O4.2 Inhaled corticosteroids and long-acting beta2-agonists and long-acting antimuscarinics in combination.O4.1 Inhaled corticosteroids and long-acting beta2-agonists in combination (ICS/LABA).O3.3 Inhaled corticosteroids versus long-acting beta2-agonists.O2.2 Phosphodiesterase type-4 inhibitors.O1.3 Assessment of response and continuation of bronchodilator therapy.O1.2.3 Long-acting bronchodilator combinations (LAMA/LABA).O1.2.2 Long-acting beta2-agonists (LABA).O1.2.1 Long-acting muscarinic antagonists (LAMA).O1.1.3 Short-acting bronchodilator combinations.
O1.1.2 Short-acting muscarinic antagonist (SAMA).O1.1.1 Short-acting beta2-agonists (SABA).C5.11 Electrocardiography and echocardiography.C5.5 High resolution computed tomography.Assessing acute response to bronchodilators Key Recommendations of the COPD-X Guidelines.COPD Guidelines Committee – Past and Present.Summary of the Changes from the previous three versions of COPD-X.Summary of the Changes – Version 2.68, October 2022.The COPD-X Plan Version 2.68, October 2022.
0 kommentar(er)
